Avid Bioservices (CDMO) Stock Forecast, Price Target & Predictions
CDMO Stock Forecast
Avid Bioservices stock forecast is as follows: an average price target of $8.00 (represents a -34.37% downside from CDMO’s last price of $12.19) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CDMO Price Target
The average price target for Avid Bioservices (CDMO) is $8.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential -34.37% downside from CDMO's last price of $12.19.
CDMO Analyst Ratings
According to 3 Wall Street analysts, Avid Bioservices's rating consensus is 'Buy'. The analyst rating breakdown for CDMO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Avid Bioservices Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 30, 2024 | Sean Dodge | RBC Capital | $8.00 | $7.56 | 5.82% | -34.37% |
The latest Avid Bioservices stock forecast, released on Apr 30, 2024 by Sean Dodge from RBC Capital, set a price target of $8.00, which represents a 5.82% increase from the stock price at the time of the forecast ($7.56), and a -34.37% decrease from CDMO last price ($12.19).
Avid Bioservices Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $12.19 | $12.19 | $12.19 |
| Upside/Downside | -100.00% | -100.00% | -34.37% |
In the current month, the average price target of Avid Bioservices stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avid Bioservices's last price of $12.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 30, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 22, 2023 | Stephens | Overweight | Overweight | Hold |
| Mar 14, 2023 | KeyBanc | - | Overweight | Upgrade |
Avid Bioservices's last stock rating was published by RBC Capital on Sep 10, 2024. The company gave CDMO a "Outperform" rating, the same as its previous rate.
Avid Bioservices Financial Forecast
Avid Bioservices Revenue Forecast
| May 27 | Jan 27 | Oct 26 | Jul 26 | May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Oct 23 | Jul 23 | May 23 | Jan 23 | Oct 22 | Jul 22 | May 22 | Jan 22 | Oct 21 | Jul 21 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.39M | $37.73M | - | $38.02M | $34.76M | $36.69M | - | $31.51M | $26.11M | $30.75M | - | $21.81M | $21.06M | $25.39M | - | $13.59M |
| Avg Forecast | $66.14M | $58.43M | $46.29M | $57.18M | $57.42M | $49.31M | $39.15M | $48.02M | $47.42M | $42.29M | $33.80M | $40.76M | $42.14M | $33.10M | $33.22M | $36.08M | $38.91M | $36.32M | $32.05M | $33.44M | $28.95M | $26.59M | $24.02M | $27.81M | $21.60M | $19.07M | $15.49M | $16.50M | $8.51M | $15.42M |
| High Forecast | $67.48M | $59.61M | $47.23M | $58.34M | $58.58M | $50.31M | $39.94M | $48.99M | $48.38M | $43.14M | $34.48M | $41.59M | $42.14M | $33.64M | $33.66M | $36.81M | $39.69M | $37.06M | $33.14M | $34.58M | $29.93M | $27.50M | $24.84M | $28.75M | $22.33M | $19.72M | $16.01M | $17.06M | $8.79M | $15.95M |
| Low Forecast | $64.64M | $57.10M | $45.24M | $55.88M | $56.11M | $48.19M | $38.26M | $46.93M | $46.34M | $41.33M | $33.03M | $39.84M | $42.14M | $32.55M | $32.77M | $35.26M | $38.02M | $35.50M | $31.17M | $32.52M | $28.15M | $25.86M | $23.36M | $27.04M | $21.00M | $18.54M | $15.06M | $16.05M | $8.27M | $15.00M |
| # Analysts | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 5 | 4 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 1.05% | - | 1.05% | 1.08% | 1.10% | - | 1.18% | 1.09% | 1.11% | - | 1.14% | 1.36% | 1.54% | - | 0.88% |
Avid Bioservices's average Quarter revenue forecast for Jan 24 based on 1 analysts is $33.10M, with a low forecast of $32.55M, and a high forecast of $33.64M. CDMO's average Quarter revenue forecast represents a 30.33% increase compared to the company's last Quarter revenue of $25.39M (Oct 23).
Avid Bioservices EBITDA Forecast
| May 27 | Jan 27 | Oct 26 | Jul 26 | May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Oct 23 | Jul 23 | May 23 | Jan 23 | Oct 22 | Jul 22 | May 22 | Jan 22 | Oct 21 | Jul 21 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 5 | 4 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.22M | $-2.16M | - | $5.07M | $-720.00K | $2.79M | - | $3.99M | $5.00M | $7.76M | - | $3.06M | $3.14M | $5.56M | - | $-1.29M |
| Avg Forecast | $2.61M | $2.31M | $1.83M | $2.26M | $2.27M | $1.95M | $1.55M | $1.90M | $1.87M | $1.67M | $1.34M | $1.61M | $4.83M | $1.31M | $1.31M | $1.43M | $4.39M | $5.50M | $402.25K | $419.74K | $3.99M | $333.77K | $301.53K | $349.01K | $6.43M | $239.32K | $194.37K | $207.11K | $-712.25K | $193.55K |
| High Forecast | $2.67M | $2.36M | $1.87M | $2.31M | $2.32M | $1.99M | $1.58M | $1.94M | $1.91M | $1.71M | $1.36M | $1.64M | $5.79M | $1.33M | $1.33M | $1.46M | $5.27M | $6.60M | $415.94K | $434.03K | $4.79M | $345.14K | $311.79K | $360.89K | $7.72M | $247.47K | $200.98K | $214.16K | $-569.80K | $200.14K |
| Low Forecast | $2.56M | $2.26M | $1.79M | $2.21M | $2.22M | $1.90M | $1.51M | $1.85M | $1.83M | $1.63M | $1.31M | $1.57M | $3.86M | $1.29M | $1.30M | $1.39M | $3.51M | $4.40M | $391.17K | $408.18K | $3.19M | $324.58K | $293.22K | $339.40K | $5.15M | $232.73K | $189.01K | $201.40K | $-854.70K | $188.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.55% | -1.52% | - | 0.92% | -1.79% | 6.64% | - | 11.95% | 16.58% | 22.24% | - | 12.80% | 16.14% | 26.85% | - | -6.69% |
2 analysts predict CDMO's average Quarter EBITDA for May 23 to be $4.39M, with a high of $5.27M and a low of $3.51M. This is -13.38% lower than Avid Bioservices's previous annual EBITDA (Jan 23) of $5.07M.
Avid Bioservices Net Income Forecast
| May 27 | Jan 27 | Oct 26 | Jul 26 | May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Oct 23 | Jul 23 | May 23 | Jan 23 | Oct 22 | Jul 22 | May 22 | Jan 22 | Oct 21 | Jul 21 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 5 | 4 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-9.51M | $-2.09M | - | $461.00K | $-1.16M | $1.56M | - | $1.23M | $3.52M | $6.30M | - | $2.21M | $2.28M | $4.73M | - | $-2.10M |
| Avg Forecast | $5.73M | $1.91M | $-1.27M | $1.91M | $954.59K | $-1.91M | $-5.41M | $-2.23M | $-2.07M | $-3.50M | $-7.48M | $-3.50M | $2.72M | $-2.97M | $-3.98M | $-1.75M | $2.47M | $3.87M | $477.29K | $2.23M | $2.25M | $3.02M | $1.59M | $2.39M | $4.63M | $-1.91M | $-3.61M | $-2.55M | $-1.16M | $-2.42M |
| High Forecast | $5.88M | $1.96M | $-1.24M | $1.96M | $979.67K | $-1.85M | $-5.25M | $-2.16M | $-2.01M | $-3.40M | $-7.26M | $-3.40M | $3.26M | $-2.88M | $-3.86M | $-1.70M | $2.97M | $4.65M | $498.42K | $2.33M | $2.70M | $3.16M | $1.66M | $2.49M | $5.56M | $-1.84M | $-3.48M | $-2.45M | $-925.76K | $-2.33M |
| Low Forecast | $5.56M | $1.85M | $-1.31M | $1.85M | $926.37K | $-1.96M | $-5.55M | $-2.29M | $-2.12M | $-3.59M | $-7.67M | $-3.59M | $2.18M | $-3.05M | $-4.08M | $-1.80M | $1.98M | $3.10M | $460.20K | $2.15M | $1.80M | $2.91M | $1.53M | $2.30M | $3.71M | $-1.99M | $-3.77M | $-2.66M | $-1.39M | $-2.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.39% | 1.20% | - | 0.12% | -2.42% | 0.70% | - | 0.41% | 2.21% | 2.64% | - | -1.16% | -0.63% | -1.86% | - | 0.87% |
Avid Bioservices's average Quarter net income forecast for May 23 is $2.47M, with a range of $1.98M to $2.97M. CDMO's average Quarter net income forecast represents a 436.40% increase compared to the company's last Quarter net income of $461.00K (Jan 23).
Avid Bioservices SG&A Forecast
| May 27 | Jan 27 | Oct 26 | Jul 26 | May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Oct 23 | Jul 23 | May 23 | Jan 23 | Oct 22 | Jul 22 | May 22 | Jan 22 | Oct 21 | Jul 21 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 5 | 4 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.56M | $6.26M | - | $7.11M | $6.83M | $6.38M | - | $5.82M | $5.03M | $4.46M | - | $4.02M | $4.17M | $3.83M | - | $3.00M |
| Avg Forecast | $12.85M | $11.35M | $8.99M | $11.11M | $11.15M | $9.58M | $7.60M | $9.33M | $9.21M | $8.21M | $6.57M | $7.92M | $7.04M | $6.43M | $6.45M | $7.01M | $6.40M | $5.54M | $6.23M | $6.50M | $5.82M | $5.17M | $4.67M | $5.40M | $8.44M | $3.70M | $3.01M | $3.21M | $1.65M | $3.00M |
| High Forecast | $13.11M | $11.58M | $9.17M | $11.33M | $11.38M | $9.77M | $7.76M | $9.52M | $9.40M | $8.38M | $6.70M | $8.08M | $8.45M | $6.53M | $6.54M | $7.15M | $7.68M | $6.64M | $6.44M | $6.72M | $6.98M | $5.34M | $4.83M | $5.59M | $10.13M | $3.83M | $3.11M | $3.31M | $1.98M | $3.10M |
| Low Forecast | $12.56M | $11.09M | $8.79M | $10.85M | $10.90M | $9.36M | $7.43M | $9.12M | $9.00M | $8.03M | $6.42M | $7.74M | $5.63M | $6.32M | $6.37M | $6.85M | $5.12M | $4.43M | $6.05M | $6.32M | $4.65M | $5.02M | $4.54M | $5.25M | $6.75M | $3.60M | $2.93M | $3.12M | $1.32M | $2.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.89% | - | 1.28% | 1.10% | 0.98% | - | 1.13% | 1.08% | 0.83% | - | 1.08% | 1.38% | 1.19% | - | 1.00% |
Avid Bioservices's average Quarter SG&A projection for Jan 24 is $6.43M, based on 1 Wall Street analysts, with a range of $6.32M to $6.53M. The forecast indicates a -1.95% fall compared to CDMO last annual SG&A of $6.56M (Oct 23).
Avid Bioservices EPS Forecast
| May 27 | Jan 27 | Oct 26 | Jul 26 | May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Oct 23 | Jul 23 | May 23 | Jan 23 | Oct 22 | Jul 22 | May 22 | Jan 22 | Oct 21 | Jul 21 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 5 | 4 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.15 | $-0.03 | - | $0.01 | $-0.02 | $0.03 | - | $0.02 | $0.05 | $0.10 | - | $0.01 | $0.01 | $0.06 | - | $-0.06 |
| Avg Forecast | $0.09 | $0.03 | $-0.02 | $0.03 | $0.01 | $-0.03 | $-0.09 | $-0.04 | $-0.03 | $-0.06 | $-0.12 | $-0.06 | $-0.04 | $-0.05 | $-0.06 | $-0.03 | $0.01 | $-0.04 | $0.01 | $0.04 | $0.02 | $0.05 | $0.03 | $0.04 | $0.01 | $-0.03 | $-0.06 | $-0.04 | $-0.16 | $-0.04 |
| High Forecast | $0.09 | $0.03 | $-0.02 | $0.03 | $0.02 | $-0.03 | $-0.08 | $-0.03 | $-0.03 | $-0.05 | $-0.11 | $-0.05 | $-0.04 | $-0.05 | $-0.06 | $-0.03 | $0.01 | $-0.04 | $0.01 | $0.04 | $0.02 | $0.05 | $0.03 | $0.04 | $0.01 | $-0.03 | $-0.05 | $-0.04 | $-0.16 | $-0.04 |
| Low Forecast | $0.09 | $0.03 | $-0.02 | $0.03 | $0.01 | $-0.03 | $-0.09 | $-0.04 | $-0.03 | $-0.06 | $-0.12 | $-0.06 | $-0.04 | $-0.05 | $-0.06 | $-0.03 | $0.01 | $-0.04 | $0.01 | $0.03 | $0.02 | $0.05 | $0.02 | $0.04 | - | $-0.03 | $-0.06 | $-0.04 | $-0.17 | $-0.04 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.40% | 1.21% | - | -0.27% | -2.48% | 0.86% | - | 0.42% | 2.00% | 2.67% | - | -0.33% | -0.18% | -1.50% | - | 1.58% |
According to 2 Wall Street analysts, Avid Bioservices's projected average Quarter EPS for May 23 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a 25.00% increase compared to CDMO previous annual EPS of $0.01 (Jan 23).
Avid Bioservices Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ACRV | Acrivon Therapeutics | $6.38 | $21.83 | 242.16% | Buy |
| LRMR | Larimar Therapeutics | $6.38 | $20.33 | 218.65% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BCYC | Bicycle Therapeutics | $20.48 | $54.40 | 165.63% | Buy |
| ANAB | AnaptysBio | $19.97 | $52.00 | 160.39% | Buy |
| KALV | KalVista Pharmaceuticals | $9.05 | $22.67 | 150.50% | Buy |
| LYRA | Lyra Therapeutics | $0.20 | $0.50 | 150.00% | Hold |
| MLYS | Mineralys Therapeutics | $12.86 | $30.00 | 133.28% | Buy |
| ADAG | Adagene | $2.22 | $5.00 | 125.23% | Buy |
| IMCR | Immunocore | $32.56 | $70.75 | 117.29% | Buy |
| KROS | Keros Therapeutics | $53.62 | $102.60 | 91.35% | Buy |
| IDYA | IDEAYA Biosciences | $25.86 | $46.58 | 80.12% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| MGTX | MeiraGTx | $5.98 | $9.00 | 50.50% | Buy |
| DYN | Dyne Therapeutics | $29.68 | $43.88 | 47.84% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| MIRM | Mirum Pharmaceuticals | $42.09 | $57.25 | 36.02% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.17 | $70.14 | 27.13% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| KDNY | Chinook Therapeutics | $40.39 | $30.00 | -25.72% | Buy |
| CDMO | Avid Bioservices | $12.19 | $8.00 | -34.37% | Buy |